“Endometriosis-Like Syndrome”: from the concept of Painful Uterine Syndrome to the use of Myometrial Botulinum Toxin injections under hysteroscopy.

Eric Bautrant, OONA FRANKE, Oona Franké, Christophe AMIEL, Thierry BENSOUSAN, Dominique THIERS BAUTRANT, Christine LEV QUE
In: Authorea, Inc. · 2020 · doi:10.22541/au.159060743.37956498 · W4233499760
preprint OA: gold CC0 ⤵ 1 in-corpus citation
📄 Open PDF View on OpenAlex View at publisher
⚙ AI-generated summary by gemini-2.5-flash-lite, 2026-07-18 ⓘ

This study explored "painful uterine syndrome" as a cause of chronic pelvic pain and dysmenorrhea, and reported positive outcomes from a pilot use of myometrial botulinum toxin injections under hysteroscopy.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

Abstract

Background: A new concept is being advanced to explain undiagnosed chronic pelvic pain, severe dysmenorrhoea, painful uterine contractions, and deep dyspareunia in women, which has been shown to be anatomically negative. Search strategy: In these “endometriosis-like” syndrome situations, there are many pathophysiological arguments supporting the existence of a visceral uterine sensitization syndrome. Data collection and analysis: These arguments are further developed and use central sensitization mechanisms, just like those for irritable bowel syndrome (IBS) or painful bladder syndrome (PBS). The name “painful uterine syndrome” (PUS) has been suggested, and a basis for a PUS diagnostic score has been established. Central sensitization and visceral sensitization mechanisms have been developed. Muscular hypertonia is common in condition of central sensitization and increased uterine contractility has been confirmed using cine magnetic resonance imaging in PUS situations. These findings led to the application of botulinum toxin (BTX) injections under hysteroscopy of the uterine myometrium in PUS. Main results: A pilot study reported the first use of BTX uterine injections under hysteroscopy in PUS and this pilot study has been analysed. It focuses on a simple and reproducible treatment procedure which shows improvement in dysmenorrhoea and dyspareunia as well as improved quality of life scores. Conclusions: Only long-term randomised studies will be able to confirm that BTX injections are useful as a treatment for this condition. The randomised long-term study, Uteroxine, started in 2020 and will shortly release its results.

My notes (saved in your browser only)

Condition tags

endometriosischronic_pelvic_paindysmenorrheadyspareuniairritable_bowel_syndrome

Citation neighborhood (2-hop)

Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. Outer rings show 2-hop neighbours — papers reached through the immediate citers/citees. [ collapse to 1-hop ]

References (48)

Cited by (1)

Source provenance

openalex
last seen: 2026-06-10T17:14:06.276822+00:00
License: CC0 · commercial use OK